These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 27852118)

  • 1. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
    Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
    Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
    JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience.
    Novo G; Di Lisi D; Bronte E; Macaione F; Accurso V; Badalamenti G; Rinaldi G; Siragusa S; Novo S; Russo A
    Oncology; 2020; 98(7):445-451. PubMed ID: 32348984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
    Jain P; Kantarjian H; Boddu PC; Nogueras-González GM; Verstovsek S; Garcia-Manero G; Borthakur G; Sasaki K; Kadia TM; Sam P; Ahaneku H; O'Brien S; Estrov Z; Ravandi F; Jabbour E; Cortes JE
    Blood Adv; 2019 Mar; 3(6):851-861. PubMed ID: 30885996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis.
    Fachi MM; Tonin FS; Leonart LP; Aguiar KS; Lenzi L; Figueiredo BC; Fernandez-Llimos F; Pontarolo R
    Eur J Cancer; 2018 Nov; 104():9-20. PubMed ID: 30296736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.
    Yilmaz M; Jabbour E
    Semin Oncol; 2015 Dec; 42(6):876-86. PubMed ID: 26615132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should vascular effects of newer treatments be addressed more completely?
    Yang EH; Watson KE; Herrmann J
    Future Oncol; 2015; 11(14):1995-8. PubMed ID: 26198824
    [No Abstract]   [Full Text] [Related]  

  • 8. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.
    Moslehi JJ; Deininger M
    J Clin Oncol; 2015 Dec; 33(35):4210-8. PubMed ID: 26371140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis.
    Cha SH; Kim K; Song YK
    Acta Oncol; 2023 Dec; 62(12):1767-1774. PubMed ID: 37787749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First line treatment with newer tyrosine kinase inhibitors in chronic myeloid leukemia associated with deep and durable molecular response - systematic review and meta-analysis.
    Gurion R; Raanani P; Vidal L; Leader A; Gafter-Gvili A
    Acta Oncol; 2016; 55(9-10):1077-1083. PubMed ID: 27560448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.
    Gover-Proaktor A; Granot G; Pasmanik-Chor M; Pasvolsky O; Shapira S; Raz O; Raanani P; Leader A
    Leuk Lymphoma; 2019 Jan; 60(1):189-199. PubMed ID: 29741440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
    Dou XL; Wang SS; Fang JL; Yu L; Ren X; Huang XJ; Jiang Q
    Zhonghua Nei Ke Za Zhi; 2018 Sep; 57(9):649-655. PubMed ID: 30180449
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy.
    Barber MC; Mauro MJ; Moslehi J
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):110-114. PubMed ID: 29222244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response.
    Hamadi A; Grigg AP; Dobie G; Burbury KL; Schwarer AP; Kwa FA; Jackson DE
    Thromb Haemost; 2019 Jul; 119(7):1112-1123. PubMed ID: 31079415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-drug discovery and cardiovascular surveillance.
    Groarke JD; Cheng S; Moslehi J
    N Engl J Med; 2013 Nov; 369(19):1779-81. PubMed ID: 24180496
    [No Abstract]   [Full Text] [Related]  

  • 16. Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia.
    Samis J; Lee P; Zimmerman D; Arceci RJ; Suttorp M; Hijiya N
    Pediatr Blood Cancer; 2016 Aug; 63(8):1332-8. PubMed ID: 27100618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors.
    Wang Y; Travers RJ; Farrell A; Lu Q; Bays JL; Stepanian A; Chen C; Jaffe IZ
    PLoS One; 2023; 18(11):e0294438. PubMed ID: 37983208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.
    Molica M; Scalzulli E; Colafigli G; Fegatelli DA; Massaro F; Latagliata R; Foà R; Breccia M
    Ann Hematol; 2018 Oct; 97(10):1803-1808. PubMed ID: 29806063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
    Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.